Welcome to our dedicated page for Aptorum Group SEC filings (Ticker: APM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptorum Group Limited's SEC filings document its foreign private issuer reporting, corporate governance and capital-structure disclosures. Form 6-K reports include annual general meeting proxy materials, shareholder voting results, board-election items, auditor ratification matters and disclosures tied to Class A Ordinary Shares and Class B Ordinary Shares.
The company's filings also cover material-event reports, material agreements, operating and financial results, registration-statement references on Form S-8 and Form F-3, and Nasdaq listing-compliance notices. These records frame APM's pharmaceutical development business alongside its governance, share structure, risk factors and public-company reporting obligations.
Aptorum Group Limited is offering 1,000,000 Class A Ordinary Shares at $2.00 per share in a registered primary offering under a prospectus supplement. Gross proceeds are $2,000,000 and estimated proceeds to the company before expenses are $1,860,000. The placement agent fee is $140,000. In a concurrent private placement, the investor will receive warrants to purchase up to 2,000,000 Class A Ordinary Shares at an exercise price of $2.00; those warrants and shares issuable upon exercise are being sold in a private exemption and are not registered here. The prospectus supplement notes a public float of approximately $15.28 million as of October 10, 2025 and states customary closing conditions and risk disclosures including the Cayman Islands holding company structure.
Aptorum Group Limited filed a Form 6-K to update investors on its previously announced merger with DiamiR Biosciences Corp.. The filing explains that Aptorum will form a wholly owned Delaware subsidiary that will merge with and into DiamiR, leaving DiamiR as a wholly owned subsidiary of Aptorum after the merger.
The merger remains subject to Aptorum shareholder approval and other closing conditions set out in the Merger Agreement dated July 14, 2025. Aptorum also reports that it has filed a proxy statement/prospectus on Form S-4 with the SEC, which provides detailed information about Aptorum, DiamiR and the merger, including financial statements for both companies and transaction-related financial information.
This Form 6-K incorporates the S-4 and related exhibits by reference into Aptorum’s existing Form S-8 and Form F-3 registration statements, meaning those registration statements now include the merger-related disclosures. The filing also includes standard forward-looking statement cautions, emphasizing that expectations about the merger and future performance involve risks and uncertainties.
Aptorum Group Ltd (APM) is proposing a business combination with DiamiR that would domesticate the Cayman Islands parent into a Delaware corporation and reorganize its share capital while issuing Aptorum Delaware shares to DiamiR shareholders under a defined Conversion Ratio. Key transaction mechanics include a Share Consolidation (reverse split) to be set by the board before domestication, issuance scenarios that would produce up to 23,499,080 Aptorum Delaware common shares to DiamiR holders under one conversion example, and the creation of a non-voting Series A preferred for existing Aptorum Class B holders in another example.
The filing discloses commercial and operational ties: an Intellectual Property License Agreement with an upfront payment of $5,000 and monthly fees of $1,200 through the earlier of the Merger closing or December 31, 2025, plus governance and board appointment rights for major stockholders. Material risks noted include regulatory uncertainty in China/Hong Kong (including PCAOB/HFCAA inspection risks), continued Nasdaq listing concerns, DiamiR’s lack of product revenues and expected ongoing losses, and execution risks tied to clinical development and funding.
Aptorum Group Limited submitted a Form 6-K to provide its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, along with a related operating and financial review. These materials give an updated picture of the company’s mid‑year financial position and performance.
The company is also incorporating these interim financial statements into its existing Form S-8 and Form F-3 registration statements, so the new information becomes part of those offering documents. The filing further lists key agreements related to its previously disclosed transaction with DiamiR, including a merger agreement, management services agreement, intellectual property license, voting and support agreement, and a form of stockholders agreement, plus the associated Inline XBRL data files.
Aptorum Group Limited filed a 6-K updating investors on its planned merger with DiamiR Biosciences Corp.. Under the previously announced Agreement and Plan of Merger, Aptorum will form a Delaware subsidiary that will merge into DiamiR, leaving DiamiR as a wholly owned subsidiary of Aptorum. The filing notes that later this week DiamiR will present at the HCW Conference, using a presentation about both companies and the merger, which is furnished as Exhibit 99.1.